Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fec + docetaxel + pertuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FEC-T plus pertuzumab is a multi-agent chemotherapy and targeted therapy regimen used primarily for the treatment of HER2-positive breast cancer. The FEC-T component consists of three chemotherapeutic agents—5-fluorouracil (F), epirubicin (E), and cyclophosphamide (C)—followed by docetaxel (T). Pertuzumab is a humanized monoclonal antibody that targets the extracellular dimerization domain of the human epidermal growth factor receptor 2 protein (HER2), blocking ligand-dependent heterodimerization with other HER family members and inhibiting downstream signaling pathways such as MAP kinase and PI3K. This results in cell growth arrest and apoptosis. Pertuzumab also mediates antibody-dependent cell-mediated cytotoxicity. The combination is indicated for neoadjuvant or adjuvant treatment in patients with HER2-positive early or locally advanced breast cancer[1][4][6].
- Other names
- fec-t + pertuzumab5-fluorouracil + epirubicin + cyclophosphamide + docetaxel + pertuzumab
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on fec + docetaxel + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fec + docetaxel + pertuzumab.